

22 December 2017

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – iQnovate Limited Completion of Convertible Note Issue

Further to the announcement of 22nd November 2017, iQnovate Ltd (IQN) is pleased to announce that the Directors have resolved to close the Convertible Note Issue. The issued Convertible Notes will convert to ordinary shares in accordance with the terms of the offering.

IQN expects to lodge an application for quotation upon completion of the conversion of the Convertible Notes to ordinary shares, currently expected to be completed in January 2018.

The ordinary shares to be issued in the placement are in a class of securities currently quoted on the National Stock Exchange of Australia.

The company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act. The shares were issued without disclosure to the recipient under Part 6D.2, in reliance on Section 708A(5)(e) of the Corporations Act.

The company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Corporations Act; and
- (b) Section 674 of the Corporations Act.

There is no excluded information for the purposes of Section 708A(7) and (8) of the Corporations Act.



Gerardo Incollingo
Company Secretary

iQnovate

Bridging science with business

iQnovate is a scientifically driven life science asset management organisation. It has exceptional organic research and development capability. This enables iQnovate to conceptualise, source, validate and commercialise biotechnology assets that have extraordinary and potentially disruptive outcomes, thus advancing human health.